Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Sells $185,478.00 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Karah Herdman Parschauer sold 8,135 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $185,478.00. Following the sale, the executive vice president directly owned 76,346 shares in the company, valued at $1,740,688.80. The trade was a 9.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $21.46 on Friday. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $18.41 and a fifty-two week high of $42.37. The stock’s 50 day simple moving average is $23.30 and its two-hundred day simple moving average is $29.14. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -3.67 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The firm had revenue of $207.28 million for the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The company’s revenue for the quarter was up 25.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.39) earnings per share. On average, analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 21st. Canaccord Genuity Group dropped their target price on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. Robert W. Baird reduced their price objective on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. HC Wainwright reduced their target price on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Finally, Leerink Partners cut their price target on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Tuesday, December 30th. Sixteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $68.29.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in Ultragenyx Pharmaceutical by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 10,263,815 shares of the biopharmaceutical company’s stock worth $236,068,000 after purchasing an additional 131,087 shares during the last quarter. State Street Corp raised its position in shares of Ultragenyx Pharmaceutical by 16.5% during the 4th quarter. State Street Corp now owns 4,303,046 shares of the biopharmaceutical company’s stock valued at $98,970,000 after buying an additional 610,559 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Ultragenyx Pharmaceutical by 26.6% in the 4th quarter. Wellington Management Group LLP now owns 2,461,910 shares of the biopharmaceutical company’s stock valued at $56,624,000 after acquiring an additional 516,781 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its position in Ultragenyx Pharmaceutical by 614.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock worth $65,205,000 after acquiring an additional 1,864,164 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Ultragenyx Pharmaceutical by 16.3% during the fourth quarter. Geode Capital Management LLC now owns 1,838,208 shares of the biopharmaceutical company’s stock worth $42,287,000 after acquiring an additional 257,701 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: Regulatory/procedural deadline — multiple firms are reminding eligible purchasers of the April 6, 2026 lead plaintiff deadline for the class action; this is a procedural notice but focuses attention on potential litigation exposure. ROSEN Deadline Notice
• Negative Sentiment: Class action filings and widespread solicitations — multiple law firms (Pomerantz, Robbins Geller, ClaimsFiler, Bronstein Gewirtz & others) have circulated notices and at least one suit has been filed alleging misstatements/omissions tied to setrusumab results; that raises potential legal and financial risk. Pomerantz Notice
• Negative Sentiment: Legal overhang amplified by media/legal alerts — additional reminders from ClaimsFiler, Robbins LLP, Furuqi & Furuqi and others increase publicity around the suit and the potential damages/settlement risk. ClaimsFiler Alert
• Negative Sentiment: Prior clinical setback cited by plaintiff counsel — Levi & Korsinsky highlights the company’s >40% decline after a Phase III setrusumab failure disclosure, framing the litigation narrative and reinforcing investor concern about program and disclosure risk. Levi & Korsinsky Alert
• Negative Sentiment: Insider selling — CFO Howard Horn disclosed multiple recent sales (including March 3 sale of 1,635 shares), feeding short‑term sentiment pressure even if not necessarily signaling company fundamentals. Insider Trades Report

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.